A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

This study is testing the drug olutasidenib (which targets a specific genetic mutation called IDH1) in combination with standard hypomethylating agent chemotherapy in patients with higher-risk blood cancers — including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and advanced myeloproliferative neoplasms. **You may be eligible if...** - You are 18 or older - You have been confirmed with higher-risk MDS, CMML, or advanced MPN - Your cancer has a documented IDH1 mutation - You are either treatment-naive (never had a hypomethylating agent) or have received prior treatment with those agents - Your liver and kidney function meet the required thresholds **You may NOT be eligible if...** - You cannot swallow oral medications or have serious GI absorption issues - You have active graft-versus-host disease from a prior stem cell transplant - You have active hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding - Your white blood cell count is above 25 x10^9/L (unless controlled by hydroxyurea) Talk to your doctor to see if this trial is right for you.